Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 5, 2025
Deals

Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz

Building in oncology, Jazz obtains targeted glioma therapy under FDA review
BioCentury | Oct 22, 2024
Product Development

Otsuka to take advantage of newly charted accelerated pathway for IgA nephropathy

BioCentury’s Clinical Report analyzes a pair of GLP-1 agonist updates, plus data from Amylyx’s ALS therapy in a new indication, and more
BioCentury | Jan 24, 2024
Data Byte

Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024

A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
BioCentury | Jan 10, 2023
Regulation

Jan. 9 Quick Takes: Arrowhead falls on unexpected high placebo response in AAT study

Plus updates from BioMarin, Santhera-ReveraGen, Day One and more
BioCentury | Dec 20, 2022
Deals

Dec. 19 Quick Takes: Sanofi, Innate deepen ties with NK licensing deal

Plus: FDA hold on Entrada’s DMD treatment and updates from Atara, AZ, LianBio-Pfizer, F2G, Protillion, and more 
BioCentury | Feb 11, 2022
Distillery Therapeutics

Structure-based design of antipsychotic without motor side effects

BioCentury | Aug 26, 2021
Finance

Neurogastrx: $60M crossover round to advance de-risked GI assets

Emerging Company Profile: Funding, assist from Vivo to land Phase III-ready Daewoong asset readies biotech to build on its CEO’s Ironwood roots
BioCentury | Oct 21, 2019
Emerging Company Profile

Inscopix: scoping out better preclinical models via live brain imaging

Inscopix uses brain imaging to make better preclinical models for CNS diseases
BioCentury | May 31, 2019
Translation in Brief

New target for Oncoceutics' GPCR-targeting compounds

Oncoceutics' compounds increase mitochondrial protease activity to kill cancer
Items per page:
1 - 10 of 484
Help Center
Username
Request a Demo
Request Training
Ask a Question